<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-164-94
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1994
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VERORAB VACCINE 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RABIES VIRUS STRAIN PM-1503-3M ANTIGEN (PROPIOLACTONE INACTIVATED)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for suspension for injection in pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        106.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SANOFI PASTEUR" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SANOFI PASTEUR
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 634]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ARAB COMPANY FOR PHARMACEUTICAL PRODUCTS (ARABIO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANOFI PASTEUR
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07BG01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>VERORAB comes in the form of a powder and solvent for suspension for injection (1 dose of powder in a vial and 0.5 ml of solvent in a prefilled syringe. Box of 1).<br />It is indicated for the prevention of rabies in children and adults. It can be used before or after exposure, as a primary vaccination or as a booster dose.</p><p>Pre-Exposure Prevention of Rabies (Pre-Exposure Vaccination):<br />Pre-exposure vaccination should be offered to subjects at high risk of contamination by the rabies virus. All those at permanent risk, such as the personnel of a diagnostic, research or production laboratory working with the rabies virus, should be vaccinated. A serological test is recommended every 6 months (see &quot;Take Special Care with VERORAB&quot;).<br />Pre-exposure vaccination should also be considered for subjects at frequent risk of exposure to the rabies virus, such as:<br />-<br />Veterinarians and their assistants, animal handlers.<br />-<br />Those who, either by profession or leisure activity, are in contact with species such as dogs, cats, skunks, raccoons, bats or other species likely to have rabies. Examples of such people are gamekeepers, hunters, forestry workers, speleologists and taxidermists.<br />-<br />Adults and children living or travelling in enzootic areas.<br />In areas where the enzootic level of rabies is low, veterinarians and assistants (including students), animal handlers and wildlife officers (gamekeepers) are considered to be at occasional risk of exposure and should receive a primary vaccination against rabies.<br />Serological tests for rabies antibodies should be performed at regular intervals in accordance with the&nbsp;subject&rsquo;s risk exposure.<br />Systematic booster injections should be administered in accordance with the subject&rsquo;s risk exposure.<br />Post-Exposure Prevention of Rabies (Post-Exposure Vaccination):<br />At the slightest risk of contamination, post-exposure vaccination should be performed as soon as possible.<br />In some countries, vaccination must be performed in a specialized rabies treatment centre.<br />Post-exposure treatment includes local, non-specific treatment of the injury, passive immunisation with rabies immunoglobulins (RIGs) and vaccination, depending on the type of injury and the status of the animal (see Tables 1 and 2).</p><p>Table 1: Course of action depending on the status of the animal:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Circumstances </strong></p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Course of Action Regarding </strong></p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Comments </strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>The animal </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>The patient </strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Animal unavailable </strong></p><p><strong>Suspect or non-suspect circumstances </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>To be taken to a rabies treatment centre for treatment</p></td><td style="vertical-align:top"><p>Treatment<sup>(b) </sup>is always completed</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dead animal </strong></p><p><strong>Suspect or non-suspect circumstances </strong></p></td><td style="vertical-align:top"><p>Send the brain to an approved laboratory for analysis</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>To be taken to a rabies treatment centre for treatment.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Treatment<sup>(b) </sup>is discontinued if the analyses are negative or, otherwise, continued</p></td></tr><tr><td style="vertical-align:top"><p><strong>Live animal </strong></p><p><strong>Non-suspect circumstances </strong></p></td><td style="vertical-align:top"><p>Place under veterinary supervision<sup>(a) </sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decision to delay rabies treatment</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Treatment<sup>(b) </sup>is adapted according to the results of veterinary supervision of the animal</p></td></tr><tr><td style="vertical-align:top"><p><strong>Suspect circumstances </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Place under veterinary supervision<sup>(a) </sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>To be taken to a rabies treatment centre for treatment.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Treatment<sup>(b) </sup>is discontinued if veterinary supervision invalidates the initial doubts, or, otherwise, continued</p></td></tr></tbody></table><p>&nbsp;</p><p>(a) In France, veterinary supervision includes 3 certificates drawn up on D0, D7, and D14 declaring the absence of signs of rabies. According to WHO recommendations, the minimum observation period under veterinary supervision for dogs and cats is 10 days.<br />(b) Treatment is recommended depending on the severity of the wound: see Table below.<br />Table 2: WHO guidelines on post-exposure treatment depending on wound severity</p><table border="1" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p><strong>Category of severity </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Type of contact with a wild<sup>(a) </sup>or domestic animal presumed or confirmed rabid or an animal that cannot be placed under supervision</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Recommended treatment </strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>I</p></td><td style="vertical-align:top"><p>Touching or feeding of animals</p><p>Licks on intact skin</p></td><td style="vertical-align:top"><p>None, if a reliable case history can be obtained</p></td></tr><tr><td style="vertical-align:top"><p>II</p></td><td style="vertical-align:top"><p>Nibbling of uncovered skin</p><p>Minor scratches or abrasions without bleeding</p><p>Licks on broken skin</p></td><td style="vertical-align:top"><p>Administer vaccine immediately<sup>(b) </sup></p></td></tr><tr><td style="vertical-align:top"><p>III</p></td><td style="vertical-align:top"><p>Single or multiple transdermal bites or scratches</p><p>Contamination of mucous membrane with saliva (i.e., licks)</p></td><td style="vertical-align:top"><p>Administer rabies immunoglobulins and vaccine immediately<sup>(b) </sup></p></td></tr></tbody></table><p>&nbsp;</p><p>(a) Contact with rodents, rabbits, or hares does not normally necessitate specific rabies treatment.<br />(b) Discontinue treatment if the animal is in good health after 10 days of observation (for cats and dogs) or if after the animal has been euthanized, the results of the search for rabies by the appropriate laboratory techniques are negative.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use VERORAB:<br />Pre-Exposure<br />If you have a fever or an acute illness: vaccination should be postponed.<br />If you are allergic to the active substance, to one of the excipients, to polymyxine B, to streptomycin or to neomycin.<br />Post-Exposure<br />Because rabies is always fatal, there is no contraindication to post-exposure vaccination.<br />Take Special Care with VERORAB:<br />As is the case with all injectable vaccines, it is recommended to have appropriate medical treatment readily available in case of anaphylactic reaction immediately after vaccination, particularly a post-exposure vaccination in subjects with a known hypersensitivity to polymyxine B, to streptomycin, or to neomycin.<br />Do not inject into the gluteal area, because weaker levels of neutralising antibodies have been observed when this area is used.</p><p>Regular serological tests are necessary. These serological tests are performed by verifying the complete neutralisation of a reference virus, by the RFFIT method (Rapid Fluorescent Focus Inhibition Test). This test should be done every 6 months in people at permanent risk of exposure, and every 2 to 3 years after each booster injection in subjects at discontinuous risk of exposure. If the antibody level is under that considered to be protective, i.e. 0.5 IU/ml (RFFIT), a booster injection should be administered.<br />When the vaccine is administered to subjects with a known immunodeficiency due to an immunosuppressive illness or a concomitant immunosuppressive treatment (such as corticosteroids), a serological test of their antibody level should be done 2 to 4 weeks after vaccination. If the antibody level is lower than that considered to be protective, i.e., 0.5 IU/ml (RFFIT), an additional injection should be administered.<br />Pregnancy and Breast Feeding:<br />Because of the severity of the disease, the vaccination schedule must not be modified as a result of pregnancy. If you discover that you are pregnant during a vaccination series, quickly consult your doctor: only your doctor can adapt the vaccination program to your situation.<br />This vaccine may be used during breast feeding.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Driving and Using Machines:<br />Post-vaccination dizziness has been frequently reported. This can temporarily affect ability to drive and use machines.</p><p>Intake or Use of Other Medicines:<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.<br />Corticosteroids and other immunosuppressive treatments can interfere with the production of antibodies and lead to the failure of the vaccination (see &quot;Take Special Care with VERORAB&quot;).<br />Immunoglobulins must be administered at a different site from that of the vaccine (the contralateral side).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Before reconstitution, the powder has a uniform white colour.<br />To reconstitute the vaccine:<br />-<br />Take the cap off the vaccine vial.<br />-<br />Inject the solvent from the prefilled syringe into the vial of powder.<br />-<br />Shake gently to obtain a homogeneous suspension of the vaccine. The reconstituted vaccine appears as a limpid liquid.<br />-<br />Immediately withdraw 0.5 ml of suspension.<br />-<br />Inject.<br />Do not inject by the intravascular route. Ensure that the needle does not penetrate a blood vessel before vaccine injection.<br />Do not administer by the subcutaneous route.<br />Because VERORAB does not contain any preservatives, the reconstituted vaccine should be used immediately.<br />Any unused product or waste should be disposed of in accordance with the regulations in effect.<br />The vaccination schedule should be adapted in accordance with the circumstances of the vaccination and the subject&rsquo;s rabies immune status.</p><p>Pre-Exposure Vaccination:<br />Three doses of VERORAB (0.5 ml) should be administered on D0, D7, and D28 or D21.<br />Booster Injection after Pre-Exposure Vaccination:<br />A booster injection of VERORAB (0.5 ml) will be administered one year after primary vaccination, followed by a booster injection every five years:<br />Table 3: Recommendations for primary vaccination and booster injections</p><table border="1" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p><strong>Primary vaccination </strong></p></td><td style="vertical-align:top"><p><strong>3 Injections </strong></p></td><td style="vertical-align:top"><p><strong>D0, D7 and D28* </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>1st booster injection </strong></p></td><td style="vertical-align:top"><p><strong>1 year later </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Subsequent booster injections </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Every five years </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* The D28 injection can be administered on D21.</p><p>VERORAB can be administered as a booster injection after primary vaccination with a rabies vaccine prepared on diploid or Vero cells.<br />Post-Exposure Vaccination:<br />First Aid: Local Treatment of the Wound<br />All bites and scratches should be immediately flushed out and washed with soap or detergent. Doing so can enable efficient elimination of the rabies virus at the infection site.<br />A 70 % alcohol solution, a tincture (or solution) of iodine, or a 0.1 % quaternary ammonium solution can then be applied (provided that there are no remaining traces of soap, because these products neutralize each other).<br />Depending on the severity of the injuries, rabies immunoglobulins (RIGs) may need to be administered in association with the vaccine. In this case, refer to the Instructions for Use in the RIG package leaflet.<br />If necessary, treatment can be supplemented by the administration of a tetanus prophylactic and/or a course of antibiotics.<br />Fully Immunised Subjects<br />Two booster doses of VERORAB (0.5 ml) should be administered on D0 and D3.<br />Administration of rabies immunoglobulins (RIGs) is not necessary and should not be done in this case, since booster injection is always followed by an anamnestic response.<br />Previously immunised subjects should be able to document the following:<br />&ndash; Full pre- or post-exposure rabies vaccination, by a cell culture vaccine or<br />&ndash; A documented rabies antibody titre &ge;0.5 IU/ml<br />In case of doubt, if the booster injection was administered more than 5 years ago, or in the case of incomplete vaccination, the patient should not be considered to be completely immunised, and complete post-exposure treatment should be initiated.<br />Table 4: Recommendations for post-exposure rabies vaccination depending on previous vaccinations</p><table border="1" cellspacing="0" cellpadding="0" style="width:672px"><tbody><tr><td style="vertical-align:top"><p>Vaccination within the last 5 years (with a cell culture VERORAB vaccine)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>2 injections: D0 and D3</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vaccination more than 5 years ago or incomplete vaccination</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Essen regimen: 5 injections: D0, D3, D7, D14 and D28, with RIGs administration if necessary</p><p>Zagreb regimen: 2 doses on D0, 1 dose on D7 and D21, with RIGs administration if necessary</p></td></tr></tbody></table><p>&nbsp;</p><p>Non-immunised Subjects<br />Five doses of VERORAB (0.5 ml) should be administered, on D0, D3, D7, D14 and D28.<br />Rabies immunoglobulins (RIGs) should be administered at the same time as the first injection in the case of a severe injury (category III according to the WHO rabies risk classification). Equine and human immunoglobulins can be used with VERORAB.<br />Internationally recognized RIG dosage is as follows:<br />Human rabies immunoglobulins: 20 IU/kg of body weight<br />Equine rabies immunoglobulins: 40 IU/kg of body weight<br />Because RIGs may partially inhibit active antibody production, no more than the recommended dose should be administered.<br />The vaccine should be injected contralaterally to the RIG administration sites.<br />In enzootic rabies areas, the administration of two injections on D0 may be justified, e.g., in the case of lesions that are extremely severe or located near the nervous system, or when the subject is immunodeficient or did not come in for a medical consultation immediately after exposure.<br />Method of Administration:<br />VERORAB is administered by the intramuscular route only, into the deltoid area in adults or the anterolateral aspect of the thigh in infants and toddlers.<br />If you forget to use VERORAB:<br />Your doctor will decide when to administer the missing dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, VERORAB may have side effects.<br />Minor local reactions: injection-site pain, injection-site erythema, injection-site oedema, injection-site pruritus and injectionsite induration.<br />General reactions: moderate fever, shivering, malaise, asthenia, headaches, dizziness, arthralgia, myalgia, gastro-intestinal disorders. (Nausea, abdominal pain).</p><p>Exceptional cases of anaphylactoid reaction, urticaria, rash.<br />In babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination.<br />If you notice side effects not mentioned in this package leaflet, inform your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Store in the refrigerator (2&deg;C - 8&deg;C). Do not freeze.<br />After reconstitution, the vaccine should be used immediately.<br />Do not use after the expiry date on the box.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is rabies virus*, Wistar Rabies PM/WI38 1503-3M strain (inactivated) (&ge;2.5 IU**/0.5 ml)<br />* produced on VERO cells<br />** quantity measured according to the international standard and the NIH test<br />&ndash; The other components are:<br />Powder: maltose and human albumin.<br />Solvent: sodium chloride and water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                VERORAB comes in the form of a powder and solvent for suspension for injection (1 dose of powder in a vial and 0.5 ml of solvent in a prefilled syringe. Box of 1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SANOFI PASTEUR SA - 2, avenue Pont Pasteur - 69007 Lyon, France</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2009
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="ltr" style="text-align:left">VERORAB comes in the form of a powder and solvent for suspension for injection (1 dose of powder in a vial and 0.5 ml of solvent in a prefilled syringe. Box of 1).<br />It is indicated for the prevention of rabies in children and adults. It can be used before or after exposure, as a primary vaccination or as a booster dose.</p><p dir="ltr" style="text-align:left">Pre-Exposure Prevention of Rabies (Pre-Exposure Vaccination):<br />Pre-exposure vaccination should be offered to subjects at high risk of contamination by the rabies virus. All those at permanent risk, such as the personnel of a diagnostic, research or production laboratory working with the rabies virus, should be vaccinated. A serological test is recommended every 6 months (see &quot;Take Special Care with VERORAB&quot;).<br />Pre-exposure vaccination should also be considered for subjects at frequent risk of exposure to the rabies virus, such as:<br />-<br />Veterinarians and their assistants, animal handlers.<br />-<br />Those who, either by profession or leisure activity, are in contact with species such as dogs, cats, skunks, raccoons, bats or other species likely to have rabies. Examples of such people are gamekeepers, hunters, forestry workers, speleologists and taxidermists.<br />-<br />Adults and children living or travelling in enzootic areas.<br />In areas where the enzootic level of rabies is low, veterinarians and assistants (including students), animal handlers and wildlife officers (gamekeepers) are considered to be at occasional risk of exposure and should receive a primary vaccination against rabies.<br />Serological tests for rabies antibodies should be performed at regular intervals in accordance with the&nbsp;subject&rsquo;s risk exposure.<br />Systematic booster injections should be administered in accordance with the subject&rsquo;s risk exposure.<br />Post-Exposure Prevention of Rabies (Post-Exposure Vaccination):<br />At the slightest risk of contamination, post-exposure vaccination should be performed as soon as possible.<br />In some countries, vaccination must be performed in a specialized rabies treatment centre.<br />Post-exposure treatment includes local, non-specific treatment of the injury, passive immunisation with rabies immunoglobulins (RIGs) and vaccination, depending on the type of injury and the status of the animal (see Tables 1 and 2).</p><p dir="ltr" style="text-align:left">Table 1: Course of action depending on the status of the animal:</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td rowspan="2" style="vertical-align:top"><p style="text-align:left"><strong>Circumstances </strong></p><p style="text-align:left">&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:left"><strong>Course of Action Regarding </strong></p><p style="text-align:left">&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p style="text-align:left"><strong>Comments </strong></p><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><strong>The animal </strong></p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left"><strong>The patient </strong></p><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><strong>Animal unavailable </strong></p><p style="text-align:left"><strong>Suspect or non-suspect circumstances </strong></p></td><td style="vertical-align:top"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left">To be taken to a rabies treatment centre for treatment</p></td><td style="vertical-align:top"><p style="text-align:left">Treatment<sup>(b) </sup>is always completed</p><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><strong>Dead animal </strong></p><p style="text-align:left"><strong>Suspect or non-suspect circumstances </strong></p></td><td style="vertical-align:top"><p style="text-align:left">Send the brain to an approved laboratory for analysis</p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left">To be taken to a rabies treatment centre for treatment.</p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left">Treatment<sup>(b) </sup>is discontinued if the analyses are negative or, otherwise, continued</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><strong>Live animal </strong></p><p style="text-align:left"><strong>Non-suspect circumstances </strong></p></td><td style="vertical-align:top"><p style="text-align:left">Place under veterinary supervision<sup>(a) </sup></p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left">Decision to delay rabies treatment</p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left">Treatment<sup>(b) </sup>is adapted according to the results of veterinary supervision of the animal</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><strong>Suspect circumstances </strong></p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left">Place under veterinary supervision<sup>(a) </sup></p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left">To be taken to a rabies treatment centre for treatment.</p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left">Treatment<sup>(b) </sup>is discontinued if veterinary supervision invalidates the initial doubts, or, otherwise, continued</p></td></tr></tbody></table><p dir="ltr" style="text-align:left">&nbsp;</p><p dir="ltr" style="text-align:left">(a) In France, veterinary supervision includes 3 certificates drawn up on D0, D7, and D14 declaring the absence of signs of rabies. According to WHO recommendations, the minimum observation period under veterinary supervision for dogs and cats is 10 days.<br />(b) Treatment is recommended depending on the severity of the wound: see Table below.<br />Table 2: WHO guidelines on post-exposure treatment depending on wound severity</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:684px"><tbody><tr><td style="vertical-align:top"><p style="text-align:left"><strong>Category of severity </strong></p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left"><strong>Type of contact with a wild<sup>(a) </sup>or domestic animal presumed or confirmed rabid or an animal that cannot be placed under supervision</strong></p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left"><strong>Recommended treatment </strong></p><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left">I</p></td><td style="vertical-align:top"><p style="text-align:left">Touching or feeding of animals</p><p style="text-align:left">Licks on intact skin</p></td><td style="vertical-align:top"><p style="text-align:left">None, if a reliable case history can be obtained</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left">II</p></td><td style="vertical-align:top"><p style="text-align:left">Nibbling of uncovered skin</p><p style="text-align:left">Minor scratches or abrasions without bleeding</p><p style="text-align:left">Licks on broken skin</p></td><td style="vertical-align:top"><p style="text-align:left">Administer vaccine immediately<sup>(b) </sup></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left">III</p></td><td style="vertical-align:top"><p style="text-align:left">Single or multiple transdermal bites or scratches</p><p style="text-align:left">Contamination of mucous membrane with saliva (i.e., licks)</p></td><td style="vertical-align:top"><p style="text-align:left">Administer rabies immunoglobulins and vaccine immediately<sup>(b) </sup></p></td></tr></tbody></table><p dir="ltr" style="text-align:left">&nbsp;</p><p dir="ltr" style="text-align:left">(a) Contact with rodents, rabbits, or hares does not normally necessitate specific rabies treatment.<br />(b) Discontinue treatment if the animal is in good health after 10 days of observation (for cats and dogs) or if after the animal has been euthanized, the results of the search for rabies by the appropriate laboratory techniques are negative.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr" style="text-align:left">Do not use VERORAB:<br />Pre-Exposure<br />If you have a fever or an acute illness: vaccination should be postponed.<br />If you are allergic to the active substance, to one of the excipients, to polymyxine B, to streptomycin or to neomycin.<br />Post-Exposure<br />Because rabies is always fatal, there is no contraindication to post-exposure vaccination.<br />Take Special Care with VERORAB:<br />As is the case with all injectable vaccines, it is recommended to have appropriate medical treatment readily available in case of anaphylactic reaction immediately after vaccination, particularly a post-exposure vaccination in subjects with a known hypersensitivity to polymyxine B, to streptomycin, or to neomycin.<br />Do not inject into the gluteal area, because weaker levels of neutralising antibodies have been observed when this area is used.</p><p dir="ltr" style="text-align:left">Regular serological tests are necessary. These serological tests are performed by verifying the complete neutralisation of a reference virus, by the RFFIT method (Rapid Fluorescent Focus Inhibition Test). This test should be done every 6 months in people at permanent risk of exposure, and every 2 to 3 years after each booster injection in subjects at discontinuous risk of exposure. If the antibody level is under that considered to be protective, i.e. 0.5 IU/ml (RFFIT), a booster injection should be administered.<br />When the vaccine is administered to subjects with a known immunodeficiency due to an immunosuppressive illness or a concomitant immunosuppressive treatment (such as corticosteroids), a serological test of their antibody level should be done 2 to 4 weeks after vaccination. If the antibody level is lower than that considered to be protective, i.e., 0.5 IU/ml (RFFIT), an additional injection should be administered.<br />Pregnancy and Breast Feeding:<br />Because of the severity of the disease, the vaccination schedule must not be modified as a result of pregnancy. If you discover that you are pregnant during a vaccination series, quickly consult your doctor: only your doctor can adapt the vaccination program to your situation.<br />This vaccine may be used during breast feeding.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Driving and Using Machines:<br />Post-vaccination dizziness has been frequently reported. This can temporarily affect ability to drive and use machines.</p><p dir="ltr" style="text-align:left">Intake or Use of Other Medicines:<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.<br />Corticosteroids and other immunosuppressive treatments can interfere with the production of antibodies and lead to the failure of the vaccination (see &quot;Take Special Care with VERORAB&quot;).<br />Immunoglobulins must be administered at a different site from that of the vaccine (the contralateral side).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr" style="text-align:left">Before reconstitution, the powder has a uniform white colour.<br />To reconstitute the vaccine:<br />-<br />Take the cap off the vaccine vial.<br />-<br />Inject the solvent from the prefilled syringe into the vial of powder.<br />-<br />Shake gently to obtain a homogeneous suspension of the vaccine. The reconstituted vaccine appears as a limpid liquid.<br />-<br />Immediately withdraw 0.5 ml of suspension.<br />-<br />Inject.<br />Do not inject by the intravascular route. Ensure that the needle does not penetrate a blood vessel before vaccine injection.<br />Do not administer by the subcutaneous route.<br />Because VERORAB does not contain any preservatives, the reconstituted vaccine should be used immediately.<br />Any unused product or waste should be disposed of in accordance with the regulations in effect.<br />The vaccination schedule should be adapted in accordance with the circumstances of the vaccination and the subject&rsquo;s rabies immune status.</p><p dir="ltr" style="text-align:left">Pre-Exposure Vaccination:<br />Three doses of VERORAB (0.5 ml) should be administered on D0, D7, and D28 or D21.<br />Booster Injection after Pre-Exposure Vaccination:<br />A booster injection of VERORAB (0.5 ml) will be administered one year after primary vaccination, followed by a booster injection every five years:<br />Table 3: Recommendations for primary vaccination and booster injections</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:684px"><tbody><tr><td style="vertical-align:top"><p style="text-align:left"><strong>Primary vaccination </strong></p></td><td style="vertical-align:top"><p style="text-align:left"><strong>3 Injections </strong></p></td><td style="vertical-align:top"><p style="text-align:left"><strong>D0, D7 and D28* </strong></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><strong>1st booster injection </strong></p></td><td style="vertical-align:top"><p style="text-align:left"><strong>1 year later </strong></p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><strong>Subsequent booster injections </strong></p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left"><strong>Every five years </strong></p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left">&nbsp;</p></td></tr></tbody></table><p dir="ltr" style="text-align:left">* The D28 injection can be administered on D21.</p><p dir="ltr" style="text-align:left">VERORAB can be administered as a booster injection after primary vaccination with a rabies vaccine prepared on diploid or Vero cells.<br />Post-Exposure Vaccination:<br />First Aid: Local Treatment of the Wound<br />All bites and scratches should be immediately flushed out and washed with soap or detergent. Doing so can enable efficient elimination of the rabies virus at the infection site.<br />A 70 % alcohol solution, a tincture (or solution) of iodine, or a 0.1 % quaternary ammonium solution can then be applied (provided that there are no remaining traces of soap, because these products neutralize each other).<br />Depending on the severity of the injuries, rabies immunoglobulins (RIGs) may need to be administered in association with the vaccine. In this case, refer to the Instructions for Use in the RIG package leaflet.<br />If necessary, treatment can be supplemented by the administration of a tetanus prophylactic and/or a course of antibiotics.<br />Fully Immunised Subjects<br />Two booster doses of VERORAB (0.5 ml) should be administered on D0 and D3.<br />Administration of rabies immunoglobulins (RIGs) is not necessary and should not be done in this case, since booster injection is always followed by an anamnestic response.<br />Previously immunised subjects should be able to document the following:<br />&ndash; Full pre- or post-exposure rabies vaccination, by a cell culture vaccine or<br />&ndash; A documented rabies antibody titre &ge;0.5 IU/ml<br />In case of doubt, if the booster injection was administered more than 5 years ago, or in the case of incomplete vaccination, the patient should not be considered to be completely immunised, and complete post-exposure treatment should be initiated.<br />Table 4: Recommendations for post-exposure rabies vaccination depending on previous vaccinations</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:672px"><tbody><tr><td style="vertical-align:top"><p style="text-align:left">Vaccination within the last 5 years (with a cell culture VERORAB vaccine)</p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left">2 injections: D0 and D3</p><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left">Vaccination more than 5 years ago or incomplete vaccination</p><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:left">Essen regimen: 5 injections: D0, D3, D7, D14 and D28, with RIGs administration if necessary</p><p style="text-align:left">Zagreb regimen: 2 doses on D0, 1 dose on D7 and D21, with RIGs administration if necessary</p></td></tr></tbody></table><p dir="ltr" style="text-align:left">&nbsp;</p><p dir="ltr" style="text-align:left">Non-immunised Subjects<br />Five doses of VERORAB (0.5 ml) should be administered, on D0, D3, D7, D14 and D28.<br />Rabies immunoglobulins (RIGs) should be administered at the same time as the first injection in the case of a severe injury (category III according to the WHO rabies risk classification). Equine and human immunoglobulins can be used with VERORAB.<br />Internationally recognized RIG dosage is as follows:<br />Human rabies immunoglobulins: 20 IU/kg of body weight<br />Equine rabies immunoglobulins: 40 IU/kg of body weight<br />Because RIGs may partially inhibit active antibody production, no more than the recommended dose should be administered.<br />The vaccine should be injected contralaterally to the RIG administration sites.<br />In enzootic rabies areas, the administration of two injections on D0 may be justified, e.g., in the case of lesions that are extremely severe or located near the nervous system, or when the subject is immunodeficient or did not come in for a medical consultation immediately after exposure.<br />Method of Administration:<br />VERORAB is administered by the intramuscular route only, into the deltoid area in adults or the anterolateral aspect of the thigh in infants and toddlers.<br />If you forget to use VERORAB:<br />Your doctor will decide when to administer the missing dose.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr" style="text-align:left">Like all medicines, VERORAB may have side effects.<br />Minor local reactions: injection-site pain, injection-site erythema, injection-site oedema, injection-site pruritus and injectionsite induration.<br />General reactions: moderate fever, shivering, malaise, asthenia, headaches, dizziness, arthralgia, myalgia, gastro-intestinal disorders. (Nausea, abdominal pain).</p><p dir="ltr" style="text-align:left">Exceptional cases of anaphylactoid reaction, urticaria, rash.<br />In babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination.<br />If you notice side effects not mentioned in this package leaflet, inform your doctor or pharmacist.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr" style="text-align:left">Keep out of the reach and sight of children.<br />Store in the refrigerator (2&deg;C - 8&deg;C). Do not freeze.<br />After reconstitution, the vaccine should be used immediately.<br />Do not use after the expiry date on the box.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr" style="text-align:left">The active substance is rabies virus*, Wistar Rabies PM/WI38 1503-3M strain (inactivated) (&ge;2.5 IU**/0.5 ml)<br />* produced on VERO cells<br />** quantity measured according to the international standard and the NIH test<br />&ndash; The other components are:<br />Powder: maltose and human albumin.<br />Solvent: sodium chloride and water for injections</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr" style="text-align:left">VERORAB comes in the form of a powder and solvent for suspension for injection (1 dose of powder in a vial and 0.5 ml of solvent in a prefilled syringe. Box of 1).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr" style="text-align:left">SANOFI PASTEUR SA - 2, avenue Pont Pasteur - 69007 Lyon, France</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2009
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VERORAB, powder and solvent for suspension for injection in prefilled syringe Rabies vaccine for human use, prepared in cell cultures (inactivated)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                After reconstitution, 1 dose (0.5 ml) contains:
Rabies virus*, Wistar Rabies PM/WI38 1503-3M strain (inactivated).................................≥ 2.5 IU**
* produced in VERO cells ** quantity measured according to the international standard and the NIH test
For a list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for suspension for injection in prefilled syringe
Uniform white-coloured powder
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VERORAB is indicated for the prevention of rabies in children and adults. It can be used before and after exposure, as a primary vaccination or as a booster dose.<br />Pre-exposure prevention of rabies (Pre-exposure vaccination)<br />Pre-exposure vaccination should be offered to subjects at high risk of contamination by the rabies virus.<br />All those at permanent risk, such as the personnel of a diagnostic, research or production laboratory working with the rabies virus, should be vaccinated. A serological test is recommended every 6 months (see section 4.4).<br />Pre-exposure vaccination should also be considered for subjects at frequent risk of exposure to the rabies virus, such as:<br />-<br />veterinarians, veterinarians&rsquo; assistants, and animal handlers<br />-<br />those who, either by profession or leisure activity, are in contact with species such as dogs, cats, skunks, raccoons, bats or other species likely to have rabies. Examples of such people are gamekeepers, hunters, forestry workers, speleologists and taxidermists.<br />-<br />adults and children living or travelling in enzootic areas.<br />A serological test can be performed every 2 to 3 years for those subject to discontinuous exposure.<br />In areas where the enzootic level of rabies is low, veterinarians and their assistants (including students), animal handlers and wildlife officers (gamekeepers) are considered to be at occasional risk of exposure and should receive a primary vaccination against rabies.<br />Serological tests for rabies antibodies should be performed at regular intervals in accordance with the subject&rsquo;s risk of exposure.</p><p>Systematic booster injections should be administered in accordance with the subject&rsquo;s risk of exposure. The frequency of booster injections is described in section 4.2.<br />Post-exposure prevention of rabies (Post-exposure vaccination):<br />Upon the slightest risk of rabies contamination, post-exposure vaccination should be performed as soon as possible.<br />In some countries, vaccination must be performed in a specialized rabies treatment centre.<br />Post-exposure treatment includes local, non-specific treatment of the injury, passive immunisation with rabies immunoglobulins (RIGs) and vaccination, depending on the type of injury and the status of the animal (see Tables 1 and 2).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Circumstances </strong></p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Course of Action Regarding </strong></p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Comments </strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>The animal </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>The patient </strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Animal unavailable </strong></p><p><strong>Suspect or non-suspect circumstances </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>To be taken to a rabies treatment centre for treatment</p></td><td style="vertical-align:top"><p>Treatment<sup>(b) </sup>is always completed</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dead animal </strong></p><p><strong>Suspect or non-suspect circumstances </strong></p></td><td style="vertical-align:top"><p>Send the brain to an approved laboratory for analysis</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>To be taken to a rabies treatment centre for treatment.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Treatment<sup>(b) </sup>is discontinued if the analyses are negative or, otherwise, continued</p></td></tr><tr><td style="vertical-align:top"><p><strong>Live animal </strong></p><p><strong>Non-suspect circumstances </strong></p></td><td style="vertical-align:top"><p>Place under veterinary supervision<sup>(a) </sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decision to delay rabies treatment</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Treatment<sup>(b) </sup>is adapted according to the results of veterinary supervision of the animal</p></td></tr><tr><td style="vertical-align:top"><p><strong>Suspect circumstances </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Place under veterinary supervision<sup>(a) </sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>To be taken to a rabies treatment centre for treatment.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Treatment<sup>(b) </sup>is discontinued if veterinary supervision invalidates the initial doubts, or, otherwise, continued</p></td></tr></tbody></table><p>(a) In France, veterinary supervision includes 3 certificates, drawn up on D0, D7, and D14, declaring the absence of signs of rabies. According to WHO recommendations, the minimum observation period under veterinary supervision for dogs and cats is 10 days.<br />(b) Treatment is recommended depending on the severity of the wound: see Table below.</p><p>Table 2: WHO guidelines on post-exposure treatment depending on wound severity</p><table border="1" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p><strong>Category of severity </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Type of contact with a wild<sup>(a) </sup>or domestic animal presumed or confirmed rabid or an animal that cannot be placed under supervision</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Recommended treatment </strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>I</p></td><td style="vertical-align:top"><p>Touching or feeding of animals</p><p>Licks on intact skin</p></td><td style="vertical-align:top"><p>None, if a reliable case history can be obtained</p></td></tr><tr><td style="vertical-align:top"><p>II</p></td><td style="vertical-align:top"><p>Nibbling of uncovered skin</p><p>Minor scratches or abrasions without bleeding</p><p>Licks on broken skin</p></td><td style="vertical-align:top"><p>Administer vaccine immediately<sup>(b) </sup></p></td></tr><tr><td style="vertical-align:top"><p>III</p></td><td style="vertical-align:top"><p>Single or multiple transdermal bites or scratches</p><p>Contamination of mucous membrane with saliva (i.e., licks)</p></td><td style="vertical-align:top"><p>Administer rabies immunoglobulins and vaccine immediately<sup>(b) </sup></p></td></tr></tbody></table><p>(a) Contact with rodents, rabbits, or hares does not normally necessitate specific rabies treatment.<br />(b) Discontinue treatment if the animal is in good health after 10 days of observation (for cats and dogs) or if, after the animal has been euthanized, the results of the search for rabies by the appropriate laboratory techniques are negative.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />VERORAB can be administered to adults and children using the same posology.<br />The vaccination schedule should be adapted in accordance with the circumstances of vaccination and the subject&#39;s rabies immune status.</p><p>4.2.1 Pre-exposure vaccination<br />Three doses of VERORAB (0.5 ml) should be administered on D0, D7 and D28 or D21.<br />Booster injection after pre-exposure vaccination<br />A VERORAB booster injection (0.5 ml) should be administered one year after primary vaccination, followed by a booster injection every 5 years (see Table 3).<br />Table 3: Recommendations for primary vaccination and booster injections</p><table border="1" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p><strong>Primary vaccination </strong></p></td><td style="vertical-align:top"><p><strong>3 Injections </strong></p></td><td style="vertical-align:top"><p><strong>D0, D7 and D28* </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>1st booster injection </strong></p></td><td style="vertical-align:top"><p><strong>1 year later </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Subsequent booster injections </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Every five years </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* The D28 injection can be administered on D21<br />VERORAB can be administered as a booster injection after primary vaccination with a cell culture rabies vaccine (a rabies vaccine prepared in VERO cells or prepared in human diploid cells (HDCV)).<br />4.2.2 Post-exposure vaccination:<br />First aid: local treatment of the wound<br />All bites and scratches should be immediately flushed out and washed with soap or detergent. Doing so can enable efficient elimination of the rabies virus at the infection site.<br />A 70 % alcohol solution, a tincture (or solution) of iodine, or a 0.1 % quaternary ammonia solution can then be applied (provided that there are no remaining traces of soap, because these two products neutralize each other).<br />Depending on the severity of the injuries, rabies immunoglobulins (RIGs) may have to be administered in association with the vaccine. In this case, refer to the instructions for use in the RIG package leaflet.<br />If necessary, treatment can be supplemented by the administration of a tetanus prophylaxis treatment and/or antibiotherapy.<br />Fully immunised subjects<br />Two booster doses of VERORAB (0.5 ml) should be administered on D0 and D3.</p><p>Administration of rabies immunoglobulins (RIGs) is not necessary and should not be performed in this case, since booster injection is always followed by an anamnestic response.<br />Previously immunised subjects should be able to document the following:<br />-<br />Full pre- or post-exposure rabies vaccination, by a cell culture vaccine or<br />-<br />A documented rabies antibody titre &ge; 0.5 IU/ml<br />In case of doubt, if the booster injection was administered more than 5 years ago, or in the case of incomplete vaccination, the patient should not be considered to be completely immunised, and complete post-exposure treatment should be initiated<br />Table 4: Recommendations for post-exposure rabies vaccination depending on previous vaccinations</p><table border="1" cellspacing="0" cellpadding="0" style="width:672px"><tbody><tr><td style="vertical-align:top"><p>Vaccination within the last 5 years (with a cell culture VERORAB vaccine)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>2 injections: D0 and D3</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vaccination more than 5 years ago or incomplete vaccination</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Essen regimen: 5 injections: D0, D3, D7, D14 and D28, with RIGs administration if necessary</p><p>Zagreb regimen: 2 doses on D0, 1 dose on D7 and D21, with RIGs administration if necessary</p></td></tr></tbody></table><p>Non-immunised subjects<br />Essen regimen<br />Five doses of VERORAB (0.5 ml) administered on D0, D3, D7, D14 and D28.<br />or<br />Zagreb regimen (schedule 2-1-1)<br />Administration of four 0.5 ml doses of VERORAB: one dose administered in the right deltoid region and one dose administered in the left deltoid region on D0, then one dose in the deltoid region on D7 and D21.<br />Whatever the regimen used, rabies immunoglobulins (RIGs) should be administered concomitantly with the first injection in the case of a severe injury (category III, according to the WHO rabies risk classification). Equine and human immunoglobulins can be used with VERORAB.<br />The internationally recognized RIG posology is as follows:<br />Human rabies immunoglobulins: 20 IU/kg of body weight<br />Equine rabies immunoglobulins: 40 IU/kg of body weight<br />Because RIGs may partially inhibit active antibody production, no more than the recommended dose should be administered.<br />The vaccine should be injected contralaterally to the RIG administration sites.<br />In enzootic rabies areas, the administration of two vaccine injections on D0 may be justified, e.g. in the case of lesions that are extremely severe or located near the nervous system, or when the subject is immunodeficient or did not come in for a medical consultation immediately after exposure.<br />Method of administration<br />VERORAB is administered by the intramuscular route only, into the deltoid area in adults or the anterolateral aspect of the thigh in infants and toddlers (see also sections 4.4 and 6.6).<br />If using the Zagreb regimen, one dose should be administered in each deltoid region (left and right) in adults on D0, then one dose on D7 and D21.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3.1
Pre-exposure
The usual contraindications to any vaccination apply: in the case of fever or acute disease, vaccination should be postponed.
Known hypersensitivity to the active substance, to one of the excipients, to polymyxine B, to streptomycin, or to neomycin.
In all cases, the risk/benefit ratio should be assessed.
4.3.2
Post-exposure
Because rabies is always fatal, there is no contraindication to post-exposure vaccination.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Injection-schedule recommendations should be followed scrupulously. Particularly in the case of post-exposure vaccination, it is imperative to take into account the status of the animal, the circumstances surrounding contact with the animal, and the nature of the wound when administering the treatment (see section 4.2).<br />As is the case with all injectable vaccines, it is recommended to have appropriate medical treatment readily available in case of anaphylactic reaction immediately after vaccination, particularly a post-exposure vaccination in subjects with a known hypersensitivity to polymyxine B, to streptomycin, or to neomycin.<br />Do not inject by the intravascular route. Ensure that the needle does not penetrate a blood vessel before vaccine injection.<br />VERORAB must not be administered by the subcutaneous route. VERORAB must not be injected into the gluteal area, because weaker levels of neutralising antibodies have been observed when this area is used.<br />Regular serological tests are necessary. These serological tests are performed by verifying the complete neutralisation of a test virus, by the RFFIT method (Rapid Fluorescent Focus Inhibition Test). This test should be done every 6 months for people at permanent risk of exposure, and every 2 to 3 years after each booster injection for subjects at discontinuous risk of exposure. If the antibody level is under that considered to be protective, i.e., 0.5IU/ml (RFFIT), a booster injection should be administered.<br />When the vaccine is administered to subjects with a known immunodeficiency due to an immunosuppressive illness or a concomitant immunosuppressive treatment (such as corticosteroids), a serological test of their antibody level should be done 2 to 4 weeks after vaccination. If the antibody level is lower than that considered to be protective, i.e., 0.5 IU/ml (RFFIT), an additional injection should be administered.<br />The potential risk of apnoea and the need for respiratory monitoring for 48-72 h should be considered when administering the primary immunisation series to very premature infants (born &le; 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Corticosteroids and other immunosuppressive treatments can interfere with the production of antibodies and lead to the failure of the vaccination (see section 4.4).<br />Immunoglobulins must be administered at a different site from that of the vaccine (the contralateral side) (see section 6.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no reliable data concerning animal teratogenicity.<br />Clinical use of the vaccine during a limited number of pregnancies to date has revealed no particular toxic or foetotoxic effect. Nonetheless, additional studies are necessary to evaluate the consequences of exposure during pregnancy.<br />Because of the severity of the disease, the vaccination schedule should not be modified as a result of pregnancy.<br />Lactation<br />This vaccine may be used during Lactation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been frequent reports of post-vaccination dizziness. This side effect can temporarily affect ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Minor local reactions: pain, erythema, oedema, pruritus and induration at the injection site<br />General reactions: moderate fever, shivering, malaise, asthenia, headaches, dizziness, arthralgia, myalgia, gastro-intestinal disorders. (nausea, abdominal pain)<br />Exceptional cases of anaphylactoid reaction, urticaria, rash.<br />Apnoea in very premature infants (born &le; 28 weeks of gestation)(see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: RABIES VACCINES, ATC Code: J07B G<br />Injection of VERORAB leads to a specific immune response. Neutralisation of the rabies virus by rabies antibodies plays a major role in the protection.<br />Because the disease is fatal, a controlled efficacy study is not possible. Nonetheless, a rabies antibody titre &ge;0.5 IU/ml (measured by RFFIT) is considered by the WHO to be indicative of protection against the disease.<br />Administering human rabies immunoglobulin (HRIG) or equine rabies immunoglobulin (ERIG) at the same time as the injecting the first 2 antirabies vaccine doses while using the Zagreb regimen may induce a mild decrease in the mean titre of neutralising antibodies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder: maltose, human albumin<br />Solvent: sodium chloride, water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rabies immunoglobulins and vaccines should never be combined in the same syringe or injected into the same site.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
After reconstitution, immediate use is recommended.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The vaccine should be stored in a refrigerator (2 &deg;C &ndash; 8 &deg;C). Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder in a vial (Type I glass) with a stopper (chlorobutyl) and a cap + 0.5 ml of solvent in prefilled syringe (Type I glass) with a plunger-stopper (chlorobromobutyl) &ndash; Box of 1</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To reconstitute the vaccine:<br />-<br />Take the cap off the vaccine vial<br />-<br />Inject the content of the prefilled syringe into the vial of powder<br />-<br />Shake gently to obtain a homogeneous suspension of the vaccine. The reconstituted vaccine appears as a clear liquid<br />-<br />Immediately withdraw 0.5 ml of the suspension<br />-<br />Inject</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SANOFI PASTEUR
2 avenue du Pont Pasteur
69007 LYON
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>